Table 2 Selected references
References | Intervention | Comparator | Perspective | Cost | Outcome | Model | Time Horizon | Discount |
|---|---|---|---|---|---|---|---|---|
Barrios et al. [21] | Polypill | Multiple monotherapy (Atorvastatin) | Payer | Direct | MACE | Markov | 10 years | 3% |
Almalki et al. [22] | Simvastatin 40 mg + Ezetimibe 10 mg | Simvastatin 40 mg | Payer | Direct | MACE | Markov | 5 years 10 years Lifetime | 3% |
Gómez-Gerique et al. [23] | Atorvastatin 80 mg | Placebo | Payer | Direct | MACE | Markov | Lifetime | 3.5% |
Ademi et al. [24] | 100% statin coverage (Low-Intensity Statin) | 82% statin coverage (Low-Intensity Statin) | Government | Direct | MACE | Markov | 5 years | 5% |
Lazar et al. [25] | Low-intensity statin (low cost) | Suggested statin by ATP III | Societal | Direct | MACE | Markov | 30 years | 3% |
Chan et al. [26] | High Dose Statin | Conventional Statin | Societal | Direct | MACE | Markov | Lifetime | 3% |
Taylor et al. [19] | Atorvastatin 80 mg | Atorvastatin 10 mg | Payer | Direct | MACE | Markov | Lifetime | 3.5% |
Lin et al. [20] | Moderate-Intensity Statin | No Statin | Payer | Direct | MACE | Markov | 10 ears | 3% |